ArticleEClinicalMedicine2025

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.

Alexander Rumyantsev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.